Mkts

ARS Pharmaceuticals, Inc.

NASDAQ: SPRY
$2.83+0.04 (+1.43%)
As of Nov 9, 9:59 AM ET

Key statistics

Day range
2.732.85
52-week range
2.4413.15
Today
Open2.80
Previous close2.83
Volume65.5K
Valuation
Market cap280.47M
P/E ratio—
EPS (TTM)-2.17
Income & risk
Dividend / yield—
Beta1.02
Avg volume1.88M
Discussion

SPRY News

Stories mentioning SPRY from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue22,68128,08732,50115,7177,97386,5812,068500.00
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development4,3363,4432,7514,0352,9523,0274,4236,896
Sales General & Admin72,20459,95574,75154,31241,10435,49219,2818,944
Total Operating Expenses82,82669,55285,69363,33145,15039,38423,81615,840
Operating Income (Loss)(60,145)(41,465)(53,192)(47,614)(37,177)47,197(21,748)(15,340)
Interest Income
Interest Expense
Other Expense(473.00)61.002,0412,7313,2373,0252,6202,824
Pretax Income
Tax Provision
Net Income (Loss)(60,618)(41,324)(51,151)(44,883)(33,940)49,934(19,128)(12,516)
Earnings Per Share (Basic)(0.61)(0.42)(0.52)(0.46)(0.35)0.52(0.20)(0.13)
Earnings Per Share (Diluted)(0.61)(0.42)(0.52)(0.46)(0.35)0.49(0.20)(0.13)
Weighted Average Shares Outstanding (Basic)99,29698,56698,80898,36298,06196,93797,03296,828
Weighted Average Shares Outstanding (Diluted)99,29698,56698,80898,36298,061102,39197,03296,828

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About SPRY

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a stock listed on the Nasdaq Stock Market under the ticker symbol SPRY. It last traded at $2.83 (Nov 9, 2026, 9:59 AM ET), up 1.4% on the day. That gives ARS Pharmaceuticals a market capitalisation of $280.5M.

Over the past 52 weeks SPRY has traded between $2.44 and $13.15.

Revenue for the quarter ended Mar 31, 2026 was $22.7M; a net loss of $60.6M. Revenue was up 184% from $8.0M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$22.7M-$60.6M-267.3%
Dec 31, 2025$28.1M-$41.3M-147.1%
Sep 30, 2025$32.5M-$51.2M-157.4%
Jun 30, 2025$15.7M-$44.9M-285.6%

From ARS Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…